Biotica and GSK to develop erythromycin macrolides
Biotica Technology, a Cambridge-based privately held biotechnology company, has signed a three-year research deal with GlaxoSmithKline to develop erythromycin-based macrolides for treating unspecified inflammatory diseases.
Biotica Technology, a Cambridge-based privately held biotechnology company, has signed a three-year research deal with GlaxoSmithKline to develop erythromycin-based macrolides for treating unspecified inflammatory diseases.
Biotica will receive an initial cash payment of up to £86m (Euro 97m) for each compound successfully developed.
GSK has also made an upfront equity investment in Biotica.
"Biotica's technology and expertise enables discovery of new medicines which could not be made by conventional means," said Dr Ming Zhang, Biotica's senior vice president of r&d.
"We had demonstrated our capacity for optimising macrolides in a successful pilot study conducted prior to completion of the agreement," he added.
Biotica
T +44 1799 532920
enquiries@biotica.com